Food and Pharmaceutical Administration on Tuesday approved The first drug in a new antibiotic class to treat urinary tract infections – for the first time for about 30 years.
The drug, a pill called Blujepa from the drug producer GSK, was approved for women for women for women – the most common type of infection in women, usually Caused by bacteria including E. coli.
Most UTIs are easy to treat, usually cleaned within a few days or weeks after a short antibiotic process.
However, he was a coaching at Mount Sinai Hospital in New York. Sovrin Shah said that bacteria that usually cause them became increasingly resistant to standard antibiotics.
In the US, more than 2.8 million antimicrobial resistant infections occur every year. Disease Control and Prevention Centers. A 2019 Study Found In more than 92% of bacteria, resistance to at least one drug may cause UTIS. Approximately 80% resistance to at least two.
Dr. Candace Granberg said it reduces the risk of drug resistance and helps to keep treatment options open.
Among the Symptoms of II, there is a burning sensation when urinating, blood, urination and urination urine. They may cause complications, including untreated, bladder infections and kidney damage.
Granberg said, we definitely need new antibiotics for non -complex UTIs, ”Granberg said.
Blujepa is part of a new class of antibiotic called TriazaasenAfthileneler who works with two key enzymes that E. coli bacteria must copy and survive.
“In a simple way, this new antibiotic uses the magic using a new binding method to prevent a bacteria’s ability to reproduce a bacteria,” Granberg said.
According to GSK, the FDA cleared a new antibiotic class for non -complicated UTIs for the last time, with the approval of Phosphomycin in 1996. (Last year, the agency approved Pivya drugs for UTIs belonging to the Penicillin pharmaceutical class.)
In two -phase clinical studies of 3,000 adults and young people, it was shown that Blujepa successfully treats 50% to 58% of patients’ infections when taken twice a day for five days compared to 43 to 47% in a group of antibiotic nitrofurantoin.
According to the 2019 report, more than half of women will experience at least one UTI in their lives and will experience an infection that repeats about 30%.
According to Tony Wood, the company’s chief scientific officer, GSK also investigates whether the drug has gonorrhea treatment.
Blujepa is expected to be present in the second half of the year. Wood did not explain how much it would cost-as a brand drug, the cost is expected to be higher than other antibiotics that have been on the market for years and with generic options.
Shah from Sina Mountain Hospital said that cost is an important issue and that physicians will probably turn to generic. Nevertheless, excessive use of the same antibiotics can support drug resistance, so a new option is useful, he added.
